The small molecule DMXAA (vadimezan) was shown to have anti-tumor effects in a mouse model [30] before its mechanism of action as a STING ligand was discovered [31], and it was tested in a clinical phase III efficacy trial of treatment of advanced non-small-cell lung cancer [32]. This evidence concerns the gene STING1 and neoplasm.